Abbott Laboratories Q3 2026: Revenue $13.01B, Adjusted EPS $1.42; Reaffirms FY Guidance
Abbott Laboratories reported Q3 2026 revenue of $13.01B, up 14.5% YoY, and adjusted EPS of $1.42. The company reaffirmed FY 2026 adjusted EPS guidance of $5.50-$5.55 and projected 6% sales growth. Notable segment performances included Diagnostics (+6.4%) and Medical Devices (+7.8%). Abbott also announced new product approvals and declared a $0.63 quarterly dividend.
How this was made
The 30-second read
Why it matters
The earnings beat and tighter guidance reinforce Abbott's growth narrative, likely supporting a short‑term rally.
Market read
First‑report earnings release for a large‑cap health‑care stock, providing fresh data for traders.
What to watch
Potential headwinds from regulatory scrutiny of new devices or competitive pricing pressure are not addressed.
Background
Abbott Laboratories is a diversified health‑care company with segments in diagnostics, nutrition, pharmaceuticals, and medical devices.
Ticker impact
Abbott reported Q3 2026 revenue of $13.01B, 14.5% YoY growth, and reaffirmed FY adjusted EPS guidance at $5.50‑$5.55.
likely upside as investors price in higher sales growth and solid guidance
Revenue beat expectations, margin expansion, and reaffirmed guidance signal continued growth, prompting buying interest.
Market effects
Healthcare sector may see uplift as Abbott's results highlight demand for diagnostics and nutrition products.
U.S. markets could open higher on the back of strong health‑care earnings.
Global investors may view Abbott's growth as a sign of resilient demand for medical devices and pharma worldwide.
Counterpoint
If the market had already priced in strong growth, the reaffirmed guidance could be seen as a neutral update.
Key entities
- companyAbbott Laboratories
U.S.-listed health‑care conglomerate reporting Q3 2026 results.